Adenosine and ATPγS protect against bacterial pneumonia-induced acute lung injury

Christine M. Gross1,2, Anita Kovacs-Kasa1,2, Mary Louise Meadows1, Mary Cherian-Shaw1, David J. Fulton1 & Alexander D. Verin1*

Lipopolysaccharide (LPS), a component of the outer membrane of gram-negative bacteria, disrupts the alveolar-capillary barrier, triggering pulmonary vascular leak thus inducing acute lung injury (ALI). Extracellular purines, adenosine and ATP, protected against ALI induced by purified LPS. In this study, we investigated whether these purines can impact vascular injury in more clinically-relevant E. coli (non-sterile LPS) murine ALI model. Mice were inoculated with live E. coli intratracheally (i.t.) with or without adenosine or a non-hydrolyzable ATP analog, adenosine 5′-(γ-thio)-triphosphate (ATPγS) added intravenously (i.v.). After 24 h of E. coli treatment, we found that injections of either adenosine or ATPγS 15 min prior or adenosine 3 h after E. coli insult significantly attenuated the E. coli-mediated increase in inflammatory responses. Furthermore, adenosine prevented weight loss, tachycardia, and compromised lung function in E. coli-exposed mice. Accordingly, treatment with adenosine or ATPγS increased oxygen saturation and reduced histopathological signs of lung injury in mice exposed to E. coli. Lastly, lung-targeting gene delivery of adenosine or ATPγS downstream effector, myosin phosphatase, significantly attenuated the E. coli-induced compromise of lung function. Collectively, our study has demonstrated that adenosine or ATPγS mitigates E. coli-induced ALI in mice and may be useful as an adjuvant therapy in future pre-clinical studies.

Acute respiratory distress syndrome (ARDS) and its less severe form, acute lung injury (ALI), are severe inflammatory disorders of the lung which involve massive leukocyte infiltration, increased vascular permeability and hypoxemia1,2. Sepsis associated with pneumonia is a major underlying cause of ALI/ARDS3. Lung instillation of gram-negative bacterial species, including Escherichia coli (E. coli) or purified components of its bacterial wall such as lipopolysaccharide (LPS), are common approaches to induce ALI in animal models4–6. While much research has been invested into the mechanisms of ALI, there remains no proven pharmacological approaches and the only treatment that has consistently reduced mortality in ALI patients is protective ventilation with low tidal volume2. Clearly, significant gaps in our knowledge remain and a greater understanding of the mechanisms by which gram-negative bacteria promote pulmonary vascular barrier dysfunction is essential to develop more effective therapies and improve the outcomes of patients with ALI.

Purines (ATP, ADP, and adenosine) can be released from the cytoplasm into the extracellular space where they serve as important intercellular signaling molecules that act via cell surface receptors7. Normally, extracellular ATP and its final purine metabolite, adenosine, are rapidly degraded to concentrations in the sub nanomolar range; although, these concentrations can temporarily rise into the micromolar range under pathological conditions8,9, including sepsis10. Purinergic cell signaling is mediated by two families of membrane-bound receptors that are designated P1 and P2 which are distinguished by their ability to recognize adenosine and ATP, respectively7. There are four subtypes of the adenosine P1 receptor which are designated A1, A2A, A2B and A3 and they all share the ability to link to G proteins8. The P2 receptor family is broadly subdivided into P2X and P2Y receptors7. There are seven P2X receptor subtypes, P2X1-P2X7 which act as ATP-gated, non-selective cation channels. In contrast, the eight P2Y receptor subtypes, P2Y1, 2, 4, 6, 11–14, are G protein-coupled receptors that recognize, with varying degrees of affinity, either ATP, ADP, UTP, UDP, or UDP-glucose7. The lung is enriched with many different types of purinergic receptors that are expressed in multiple cell types and mediate...
important functions including pulmonary vasodilation\textsuperscript{11}, bronchoconstriction\textsuperscript{12,13}, immune cell modulation\textsuperscript{14}, ciliary beat frequency\textsuperscript{15,16}, and pulmonary surfactant release\textsuperscript{17}. We have previously reported that an intravenous bolus of either adenosine 5’-(γ-thio)-triphosphate (ATPγS), a non-hydrolyzable ATP analog\textsuperscript{18}, or adenosine\textsuperscript{19} protects against pulmonary inflammation and edema in a sterile model of LPS-induced ALI in mice and this is supported by other reports that either extracellular ATP or adenosine provides protection against sepsis\textsuperscript{20,21} and ischemia-reperfusion\textsuperscript{22,23}. In addition, the P2Y1 and P2Y2 receptors have been shown to mediate improved survival and reduced pulmonary capillary protein leak in mice infected with the gram-negative bacteria \textit{Pseudomonas aeruginosa}\textsuperscript{24}. ATP administration has also been shown to improve survival and reduce bacterial counts in murine models of gram-negative and gram-positive sepsis induced by \textit{E. coli} and \textit{Staphylococcus aureus}\textsuperscript{25}, respectively. Similarly, extracellular adenosine has been shown to improve survival and reduced lung bacterial counts in mice exposed to gram-positive \textit{Streptococcus pneumoniae}\textsuperscript{26}.

Nevertheless, despite the above supportive findings, it is not yet known whether therapeutic intervention with extracellular purines can improve lung function and hemodynamic parameters in a mouse model of gram-negative bacterial pneumonia. Therefore, this study was undertaken to investigate the pre-clinical efficacy of the purines, adenosine and ATPγS, in limiting \textit{E. coli} pneumonia-induced inflammation and lung injury. We demonstrated that after 24 h of i.t. \textit{E. coli} inoculation, i.v. injections of either adenosine or ATPγS 15 min prior or adenosine 3 h after \textit{E. coli} insult significantly attenuated the \textit{E. coli}-mediated increase in protein extravasation and cells infiltration into the bronchoalveolar lavage fluid (BALF). Furthermore, adenosine prevented weight loss, tachycardia, and compromised lung function in \textit{E. coli}-exposed mice. Accordingly, treatment with adenosine or ATPγS increased oxygen saturation and reduced histopathological signs of lung injury in mice exposed to \textit{E. coli}. Further, lung-targeting delivery\textsuperscript{27} of constitutively active (C/A) MYPT1\textsuperscript{28}, a downstream adenosine and ATPγS effector\textsuperscript{29,30}, protected lung function from \textit{E. coli}-induced lung injury. Along with our published\textsuperscript{31} results on the protective effects of ATPγS and adenosine in sterile ALI model induced by purified LPS, these data suggested promising pre-clinical potential of these purines for the treatment of ALI/ARDS.

Materials and methods

Animals. All animal care and experimental procedures were approved by the Institutional Animal Care and Use Committee of Augusta University (Augusta, GA). Adult male C57BL/6N Hsd mice (7–8 weeks; Envigo, Indianapolis, IN) were used in all experiments. Mice were maintained at a room temperature of 23 ± 1 °C and exposed to a 12 h alternating light/dark cycle. The animals were fed standard rodent chow (Teklad no. 2918; Envigo) and given tap water ad libitum.

\textit{Escherichia coli} pneumonia induced lung injury model. \textit{Escherichia coli} (\textit{E. coli}) (ATCC® 25922\textsuperscript{r}); Manassas, VA), a clinically isolated strain, was inoculated from one colony on Luria Bertani (LB) agar plates into 5 ml LB broth to grow at 37 °C overnight and then, re-inoculated (1:10) into 10 ml LB broth to grow to mid-logarithmic phase for another 2 h. Bacteria were harvested by centrifugation at 5000 g for 10 min, washed twice in 0.9% saline, re-suspended in 10 ml 0.9% saline, and quantified by measuring the optical density at 600 nm (OD\textsubscript{600}) using a spectrophotometer (1 OD\textsubscript{600} = 1 × 10\textsuperscript{8} \textit{E. coli}/ml). Mice were anesthetized by intraperitoneal (i.p.) injection of ketamine (100 mg/kg) and xylazine-HCl (10 mg/kg), then neck midline incision was performed, and the trachea and right internal jugular vein (IJV) were exposed. Fifteen minutes before instillation, mice received either adenosine, ATPγS (final calculated plasma concentration 100 μM for both; Sigma-Aldrich, St. Louis, MO), or vehicle (0.9% saline) intravenously (i.v.) through the right IJV, then mice were inoculated intratracheally (i.t.) with 1 × 10\textsuperscript{5} bacteria in 30 μl of \textit{E. coli} suspension in 0.9% saline or 30 μl of 0.9% sterile saline. In post-treatment experiments, adenosine was added 3 h after \textit{E. coli} insult in the same fashion as described above. Mice were weighed at the start of the experiment and after 24 h. Mice were sacrificed 24 h after infection by intraperitoneal (i.p.) injection of ketamine (500 mg/kg) and xylazine-HCl (50 mg/kg), then bronchoalveolar lavage fluid (BALF) was collected and analyzed as described below. Lungs were flushed with ice-cold EDTA-1 × PBS and then harvested and fixed in 10% formalin for immuno-histochemical evaluation (described below). Alternatively, 24 h after \textit{E. coli} insult, the mice were anesthetized with an i.p. injection of ketamine (100 mg/kg) and xylazine-HCl (10 mg/kg) and lung function studies were performed as described below.

Isolation of BALF. BALF was obtained by injecting and aspirating 1 ml 1 × PBS via a tracheal cannula, as we have previously described\textsuperscript{31}. The cells in the BALF were precipitated at 2500 g for 10 min, then the supernatant was analyzed for protein content using the BCA Protein Assay (Thermo Fisher Scientific, Rockford, IL). The cell pellet was re-suspended in water for 15 s to lyse the red blood cells, and then the salt concentration was adjusted by the addition of 20× PBS. The total cell count was determined by a hemocytometer\textsuperscript{31}.

Histopathological analysis of the mouse lung. Lung sections (4 μm) from paraffin-embedded blocks were prepared as we have described\textsuperscript{31}, then were cut, mounted on treated slides (Superfrost plus; Fisher Scientific, Pittsburgh, PA), deparaffinized in xylene, and passed through a graded series of alcohol solutions to distillate water\textsuperscript{31}. Slides were stained with hematoxylin and eosin (H & E), and then dehydrated, cleared, and mounted with Cytoseal 60 (Thermo Fisher Scientific).

Myeloperoxidase staining. For myeloperoxidase (MPO) staining lung sections (5 μm) were processed and mounted on the slides as described above, then endogenous peroxidases were quenched with 0.3% H\textsubscript{2}O\textsubscript{2} for 5 min followed by two rinses with distilled water. MPO staining was performed using anti-MPO antibody (1:100 dilution, Abcam, Cambridge, MA) following by incubation with a secondary peroxidase-labeled polymer conjugated to goat anti-rabbit IgG (Envision +, Dako Corporation) as we have previously described in details\textsuperscript{31}.
Figure 1. Adenosine pretreatment significantly attenuates *E. coli*-mediated protein extravasation and cell infiltration in BALF in a murine model of ALI. Either adenosine (100 µM) or saline (vehicle) was instilled intravenously 15 min before *E. coli* (intratracheally, for 24 h) challenge. The mice were anesthetized, and the bronchoalveolar lavage fluid (BALF) was collected and centrifuged. (A) The protein content (mg/ml) was determined in the resultant supernatants using a BCA protein assay kit. (B) The cell number in BALF was determined using a hemocytometer. Values are mean ± SEM, n = 4–6. *P* < 0.05 vs. Vehicle, †P < 0.05 vs. Vehicle + *E. coli*.

Bound antibody was detected with 3,3′-diaminobenzidine (DAB + substrate kit, Dako Corporation). Slides were counterstained with Mayer’s hematoxylin and then dehydrated, cleared, and mounted with Cytoseal 60 (Thermo Fisher Scientific). To assess the extent of histological lung injury in mice a designated scoring system (Lung Injury Score) published by the American Thoracic Society was utilized as we have previously described in details.

Assessment of respiratory mechanics. Parameters of lung function such as pressure–volume curves, transcutaneous oxygen saturation and heart rate were evaluated in anesthetized mice (i.p. injection of ketamine (100 mg/kg) and xylazine-HCl (10 mg/kg) twenty-four hours after *E. coli* exposure as we have previously described. After the measurement of respiratory function, the mice were sacrificed by thoracotomy.

In vivo DNA delivery into mouse lung endothelium with JetPEI. In vivo gene delivery was performed as we have previously described. Briefly, constitutively-active (C/A) MYPT1 in pcDNA 3.1 mammalian expression plasmid or control empty plasmid pcDNA 3.1 (40 µg each) were incubated with glucose and jetPEI reagent (Polyplus-transfection Inc, New York, NY), as per manufactures instruction for 15~30 min. Then, the cDNA/jetPEI complexes were injected into 7~8 week old male mice via the tail vein and 72 h later mice were treated with *E. coli* and changes in respiratory mechanics were assessed as described above. Expression of MYPT1 was assessed in tissue extracts from snap-frozen lung by immunoblotting with anti-MYPT1 antibody using actin as a loading control.

Statistical analysis. Statistical analysis was performed based on at least three independent experiments using GraphPad Prism version 5.01 for Windows (GraphPad Software, San Diego, CA). The mean ± SEM was calculated in all experiments, and statistical significance was determined by one-way analysis of variance (for ≥ 3 groups). For the analysis of variance, Newman-Kuels post-hoc testing was employed. A value of *P* < 0.05 was considered significant.

Ethical issues. All methods were carried out in accordance with relevant guidelines and regulations. Named Augusta University institutional committees approved all experimental protocols.

Results

Previous studies have shown that adenosine and ATPγS provide protection against a sterile model of LPS-induced lung injury. Therefore, in this study, we further explored whether these purines can limit lung injury associated with bacteria (*E. coli*)-induced pneumonia. Mice were administered intravenous adenosine, ATPγS, or saline (vehicle) which was followed 15 min later by intratracheal inoculation of saline or the *E. coli* (strain ATCC 25922, 1 × 10⁸ bacteria in 30 µl suspension). 24 h after inoculation analysis of the BALF revealed that pretreatment with adenosine (Fig. 1A) or ATPγS (Fig. 2A) reduced *E. coli* stimulated protein extravasation into the airspaces. Consistent with these results, microscopic analysis of the BALF indicated that mice pretreated with adenosine or ATPγS exhibited significantly less cellular infiltration following *E. coli* exposure (Fig. 1B and 2B). Accordingly, adenosine added 3 h after *E. coli* insult significantly attenuated increase in BALF protein and cell count induced by *E. coli* (Supplemental Fig. 1). Analysis of lung mechanics revealed that *E. coli* exposure resulted in a downward displacement of the pressure–volume curve in vehicle treated mice which was not observed in adenosine treated mice in which lung mechanics were preserved (Fig. 3A). Accordingly, adenosine significantly improved oxygen saturation in *E. coli* inoculated mice (Fig. 3B). In addition, adenosine (Fig. 4A) treatment significantly reduced the tachycardia induced by *E. coli*. Weight loss was observed in mice exposed to *E. coli*, presumably due to anorexia or dehydration. Adenosine (Fig. 4B) pretreatment attenuated the *E. coli* induced weight loss. While the effects of ATPγS on *E. coli*-induced weight loss, lung mechanics and tachycardia have similar response patterns, they were not statistically significant (Supplemental Fig. 2A and 3). In contrary, similar to adenosine (Fig. 2B), ATPγS (Supplemental Fig. 3B) restored oxygen saturation compromised by *E. coli*.
**Figure 2.** ATPγS pretreatment significantly attenuates *E. coli* mediated protein extravasation and cell infiltration in BALF in a murine model of ALI. Either ATPγS (100 μM), or saline (vehicle) was instilled intravenously 15 min before *E. coli* (intratracheally, for 24 h) challenge. The mice were anesthetized, and the bronchoalveolar lavage fluid (BALF) was collected and centrifuged. (A) The protein content (mg/ml) was determined in the resultant supernatants using a BCA protein assay kit. (B) The cells were counted using a hemocytometer. Values are mean ± SEM, n = 4–6. *P < 0.05 vs. Vehicle, † P < 0.05 vs. Vehicle + *E. coli*.

**Figure 3.** Adenosine attenuates *E. coli*-induced compromise of lung respiratory functions. (A) Mice were intravenously injected with either adenosine (100 μM) or saline (vehicle) followed after 15 min by intratracheal inoculation with *E. coli*. Lung mechanics was evaluated in anesthetized mice (i.p. injection of ketamine (100 mg/kg) and xylazine-HCl (10 mg/kg)) twenty-four hours after *E. coli* exposure as we have previously described31. After the measurement of respiratory function, the mice were sacrificed by thoracotomy33. The data represent pressure–volume loops for four groups with two curves: one for inhalation (upper curve) and one for exhalation (lower curve of the same color) events. Values are mean ± SEM, n = 4–6. *P < 0.05 vs. Vehicle, † P < 0.05 vs. Vehicle + *E. coli*. (B) Mice were intravenously injected with either adenosine (100 μM), or saline (vehicle) followed after 15 min by intratracheal inoculation with *E. coli*. After 24 h, transcutaneous oxygen saturation was monitored via a small animal pulse oximeter by placing the non-invasive sensor on the neck. Values are mean ± SEM, n = 4–6. *P < 0.05 vs. Vehicle, † P < 0.05 vs. Vehicle + *E. coli*.

**Figure 4.** Adenosine prevents the increase in heart rate and weight loss in *E. coli* challenged mice. (A) Mice were intravenously injected with either adenosine (100 μM) or saline (vehicle) followed after 15 min by intratracheal inoculation with *E. coli*. After 24 h, heart rate was monitored via a small animal pulse oximeter by placing the non-invasive sensor on the neck. Values are mean ± SEM, n = 4–6. *P < 0.05 vs. Vehicle, † P < 0.05 vs. Vehicle + *E. coli*. (B) Mice were intravenously injected with either adenosine (100 μM) or saline (vehicle) followed after 15 min by intratracheal inoculation with *E. coli*. Mice were weighed at the start of the experiment and at 24 h before termination of the experiment. Values are mean ± SEM, n = 4–6. *P < 0.05 vs. Vehicle, † P < 0.05 vs. Vehicle + *E. coli*.
insult. Histological assessment of lung sections stained with H & E and MPO indicated that treatment with either adenosine (Fig. 5A) or ATPγS (Fig. 6A) attenuated the morphological changes induced by *E. coli* instillation. Indeed, evidence of leukocyte and red blood cell extravasation, hyaline membranes, and proteinaceous debris accumulation in the alveoli were all significantly reduced in the lungs of *E. coli* exposed mice that were treated with either adenosine (Fig. 5A) or ATPγS (Fig. 6A). In addition, the severity of lung injury was assessed using a semi-quantitative histopathological scoring system that encompasses the extent of neutrophil infiltration and serum protein accumulation within the airspaces, thickening of the alveolar septa, and the presence of hyaline membranes. The intratracheal instillation of *E. coli* significantly increased the lung injury score in vehicle treated mice but not in either adenosine (Fig. 5B) or ATPγS (Fig. 6B) treated mice.

We have recently shown that both adenosine and ATPγS protect endothelial barrier function via MLCP-mediated mechanisms in vitro. In order to evaluate the role of MLCP activity in *E. coli*-induced compromise of lung function we utilized targeting delivery of constitutively active (C/A) MLCP regulatory subunit (MYPT1) into the lung endothelium using jetPEI approach into the lung endothelium using jetPEI approach. pcDNA-C/A MYPT1 plasmid or empty vector pcDNA plasmid (both 40 µg), were incubated with glucose and the jetPEI reagent for 15–30 min. Then, the resulting DNA-jetPEI complexes were injected into mice via the tail vein and after 72 h *E. coli* suspension was introduced and lung function was evaluated as we described above. Figure 7 demonstrated that introduction of (C/A) MYPT1 significantly attenuated *E. coli*-induced loss of lung function suggesting the involvement of MLCP activity in lung function preservation in *E. coli*-induced ALI model in mice.

**Discussion**

A defining characteristic of pathophysiology of ALI is the massive pulmonary inflammation that compromises the microvascular endothelial barrier leading to the extravasation of protein-rich fluid in alveolar and extra-alveolar spaces. In the current study we have used a clinically relevant, non-sterile mouse model of gram-negative bacterial pneumonia to demonstrate that the intravenous administration of purinergic agonists, either adenosine or ATPγS, provides protection against *E. coli* induced neutrophil infiltration and protein exudation into the lungs, improves oxygen saturation and mitigates lung injury. Adenosine treatment significantly blunted *E. coli* mediated changes in body weight, lung mechanics, and heart rate. This data is in agreement with our previous studies showing that an intravenous bolus of either ATPγS or adenosine protects against inflammation and pulmonary edema in a sterile murine model of LPS induced ALI. Although this study does not address the receptor-mediated mechanism underlying adenosine and ATP mediated lung protection, earlier studies by our group have indicated that the A2 receptors are involved in adenosine-induced endothelial barrier enhancement in human pulmonary macro- and microvascular endothelial cells. In contrary, ATP and ATPγS were shown to improve human pulmonary endothelial barrier function through the activation of P2Y receptors. While disruption of alveolar barrier leading to pulmonary edema is prominent feature of ALI, other factors such as endothelial and epithelial cells apoptosis may contribute to ALI development. Inhibitors of apoptosis improves

---

**Figure 5.** Adenosine pretreatment significantly attenuates lung injury in *E. coli* challenged mice. Mice were intravenously injected with either adenosine (100 µM) or saline (vehicle) followed after 15 min by intratracheal inoculation with *E. coli*. Lung sections were evaluated for inflammatory changes after hematoxylin and eosin staining (A, upper panel), neutrophil infiltration after MPO staining (A, lower panel), (representative micrographs are shown), and scored for lung injury (B). Values are mean ± SEM, n = 4–6. *P* < 0.05 vs. Vehicle, †P < 0.05 vs. Vehicle + *E. coli*. 

---
Edemagenic factors, like LPS, produce apoptotic responses in human alveolar epithelial cells. However, whether extracellular purines can oppose *E. coli*-induced ALI via inhibition of apoptosis is unknown and may be subject for future studies.

The adenosine A2 receptor is a G-protein coupled receptor linked to Gαs which stimulates adenylyl cyclase, resulting in cAMP accumulation following by protein kinase A (PKA) activation. In human lung macrovascular and microvascular EC (HPAEC and HLMVEC, respectively), the activation of cAMP-dependent signaling pathways results in improved barrier function. In contrary, ATPγS-induced EC barrier enhancement in both cell types involves Gi-mediated cAMP-independent PKA activation. The mechanisms of cAMP-independent PKA activation are ill defined, but our recently published data suggested that they may involve interaction of PKA with PKA-anchoring protein 2 (AKAP2). Both, adenosine- and ATPγS-induced EC barrier enhancement involve activation of MLCP leading to inhibition of EC contractile responses. Further, MLCP is directly involved in survival in rodents ALI models. Edemagenic factors, like LPS, produce apoptotic responses in human alveolar epithelial cells. However, whether extracellular purines can oppose *E. coli*-induced ALI via inhibition of apoptosis is unknown and may be subject for future studies.

The adenosine A2 receptor is a G-protein coupled receptor linked to Gαs which stimulates adenylyl cyclase, resulting in cAMP accumulation following by protein kinase A (PKA) activation. In human lung macrovascular and microvascular EC (HPAEC and HLMVEC, respectively), the activation of cAMP-dependent signaling pathways results in improved barrier function. In contrary, ATPγS-induced EC barrier enhancement in both cell types involves Gi-mediated cAMP-independent PKA activation. The mechanisms of cAMP-independent PKA activation are ill defined, but our recently published data suggested that they may involve interaction of PKA with PKA-anchoring protein 2 (AKAP2). Both, adenosine- and ATPγS-induced EC barrier enhancement involve activation of MLCP leading to inhibition of EC contractile responses. Further, MLCP is directly involved in
lungs vascular barrier protection against LPS-induced ALI in murine model22. Consistent with these data, our results demonstrated the involvement of MLCP activity in the protection of lung function against E. coli-induced lung injury highlighting the key role of MLCP activation in the lung function preservation in both sterile and non-sterile ALI models.

Several studies have shown that extracellular ATP is protective in ALI. In Pseudomonas aeruginosa infected P2Y1/P2Y2−/− mice, investigators found diminished survival and elevated protein content in the alveolar spaces, suggesting that P2Y1 and P2Y2 are important for maintaining the alveolar-capillary barrier34. An intravenous infusion of ATP improved systemic and pulmonary hemodynamics, cardiac output, stroke volume, arterial blood gases, pH, lung mechanics, and survival in mechanically ventilated piglets with sepsis caused by the gram-positive Group B β-hemolytic streptococci38. In a recent study, an intraperitoneal injection of ATP protected mice from E. coli and Staphylococcus aureus mediated mortality and reduced bacterial counts in peritoneal lavage34. Improved survival was found to be dependent on P2X7 receptors which signal to repress the inflammasome-dependent activation of Caspase-1, and was mediated by intact ATP and not its degradation products25. Similarly, ATP administration was found to be protective in a mouse model of polymicrobial sepsis with the authors reporting that P2X7 receptor signaling on macrophages was crucial for mediating bacterial killing and reducing pulmonary inflammation25. In contrast to these studies, others have shown that P2X7−/− mice exposed to LPS exhibited improved lung mechanics, reduced neutrophil pulmonary infiltration, and improved histopathological findings including less alveolar collapse and fiber deposition35. These studies highlight potential differences between sterile and non-sterile models of ALI and stress the importance of performing studies in multiple animal models. In addition, these results imply that ATP can have both physiological and pathological roles during the resolution of an infection. Purines, including ATP and adenosine, are generally considered “danger molecules” that are released to the extracellular space at sites of tissue injury to activate circulating immune cells and stimulate migration towards the site of injury. Accordingly, these purinergic nucleotides play an important role in resolving an active infection but can also cause excessive or chronic inflammation1. Along these lines, extracellular ATP has been shown to induce chemokine secretion and neutrophil chemotaxis24, which is consistent with the findings of others and is likely P2Y receptor mediated40,41. In addition, ATP may be involved in the formation of inflammasomes by binding to P2X7 receptors and promoting inflammatory responses42,43.

These findings contrast those of our present study and past publications18, which collectively found that intravenous ATP or adenosine administration reduced total leukocyte and neutrophil infiltration in the E. coli and LPS challenged mouse lung, which suggests that ATP restrains leukocyte migration. The reasons for these differences are unclear, but may be attributed to: (1) the method of ATP/ATPγS administration: an intraperitoneal injection of ATP will first enter the lymphatic circulation and travel through the lymph nodes eliciting an immune response before ultimately entering into the bloodstream, while an intravenous delivery route, as used in our study, will first pass the pulmonary endothelium where ATP may strengthen barrier function; and (2) the ATPγS we employed is essentially non-hydrolyzable. The latter point is important as numerous studies suggest that ATP can hydrolyze and its degradation products can act as signaling molecules. Accordingly, these purinergic nucleotides play an important role in resolving an active infection but can also cause excessive or chronic inflammation1. Along these lines, extracellular ATP has been shown to induce chemokine secretion and neutrophil chemotaxis24, which is consistent with the findings of others and is likely P2Y receptor mediated40,41. In addition, ATP may be involved in the formation of inflammasomes by binding to P2X7 receptors and promoting inflammatory responses42,43.

While controversy remains over the cell type and receptor(s) involved, adenosine administration has been shown to be protective in many models of ALI5,19,21,23,48-55. Indeed, our present conclusion that intravenous ATPγS administration reduced total leukocyte and neutrophil infiltration in the E. coli and LPS challenged mouse lung, which suggests that ATP restrains leukocyte migration. The reasons for these differences are unclear, but may be attributed to: (1) the method of ATP/ATPγS administration: an intraperitoneal injection of ATP will first enter the lymphatic circulation and travel through the lymph nodes eliciting an immune response before ultimately entering into the bloodstream, while an intravenous delivery route, as used in our study, will first pass the pulmonary endothelium where ATP may strengthen barrier function; and (2) the ATPγS we employed is essentially non-hydrolyzable. The latter point is important as numerous studies suggest that ATP can hydrolyze and its degradation products can act as signaling molecules. Accordingly, these purinergic nucleotides play an important role in resolving an active infection but can also cause excessive or chronic inflammation1. Along these lines, extracellular ATP has been shown to induce chemokine secretion and neutrophil chemotaxis24, which is consistent with the findings of others and is likely P2Y receptor mediated40,41. In addition, ATP may be involved in the formation of inflammasomes by binding to P2X7 receptors and promoting inflammatory responses42,43.

While controversy remains over the cell type and receptor(s) involved, adenosine administration has been shown to be protective in many models of ALI5,19,21,23,48-55. Indeed, our present conclusion that intravenous ATPγS administration reduced total leukocyte and neutrophil infiltration in the E. coli and LPS challenged mouse lung, which suggests that ATP restrains leukocyte migration. The reasons for these differences are unclear, but may be attributed to: (1) the method of ATP/ATPγS administration: an intraperitoneal injection of ATP will first enter the lymphatic circulation and travel through the lymph nodes eliciting an immune response before ultimately entering into the bloodstream, while an intravenous delivery route, as used in our study, will first pass the pulmonary endothelium where ATP may strengthen barrier function; and (2) the ATPγS we employed is essentially non-hydrolyzable. The latter point is important as numerous studies suggest that ATP can hydrolyze and its degradation products can act as signaling molecules. Accordingly, these purinergic nucleotides play an important role in resolving an active infection but can also cause excessive or chronic inflammation1. Along these lines, extracellular ATP has been shown to induce chemokine secretion and neutrophil chemotaxis24, which is consistent with the findings of others and is likely P2Y receptor mediated40,41. In addition, ATP may be involved in the formation of inflammasomes by binding to P2X7 receptors and promoting inflammatory responses42,43.
In conclusion, our data demonstrates that the purinergic agonists, adenosine and ATPγS, given intravenously can attenuate lung injury induced by E. coli pneumonia and this occurs via a reduction in inflammation and pulmonary microvascular protein leak. Based on these findings, we speculate that purinergic receptor modulation may pave the way for future pre-clinical studies on the protective role of extracellular purines in ALI. Further studies will be required to elucidate the mechanisms of adenosine and ATPγS mediated lung protection and to clarify the role of individual purinergic receptors during bacterial pneumonia.

Received: 30 April 2019; Accepted: 8 October 2020
Published online: 22 October 2020

References
1. Ware, L. B. & Matthay, M. A. The acute respiratory distress syndrome. *N. Engl. J. Med.* **342**, 1334–1349 (2000).
2. Matthay, M. A., Ware, L. B. & Zimmerman, G. A. The acute respiratory distress syndrome. *J. Clin. Invest.* **122**, 2731–2740 (2012).
3. Rubenfeld, G. D. et al. Incidence and outcomes of acute lung injury. *N. Engl. J. Med.* **353**, 1685–1693 (2005).
4. Mizgerd, J. P. & Serrett, S. J. Animal models of human pneumonia. *Am. J. Physiol. Lung Cell Mol. Physiol.* **294**, L387–398 (2008).
5. Chan, H., Bai, C. & Wang, X. The value of the lipopolysaccharide-induced acute lung injury model in respiratory medicine. *Expert Rev. Respir. Med.* **4**, 773–783 (2010).
6. Matute-Bello, G., Frevert, C. W. & Martin, T. R. Animal models of acute lung injury. *Am. J. Physiol. Lung Cell Mol. Physiol.* **295**, L379–399 (2008).
7. Ralevic, V. & Dunn, W. R. Purinergic transmission in blood vessels. *Annu. Rev. Pharmacol. Toxicol.* **35**, 215–239 (1995).
8. Hasko, G. & Cronstein, B. N. Adenosine: an endogenous regulator of innate immunity. *Trends Immunol.* **25**, 33–39 (2004).
9. Skrabanja, A. T., Bouman, E. A. & Dagnelie, P. C. Potential value of adenosine 5’-triphosphate (ATP) and adenosine in anaesthesia and intensive care medicine. *Br. J. Anaesth.* **94**, 556–562 (2005).
10. Martin, C., Leone, M., Viviani, X., Ayem, M. I. & Guieu, R. High adenosine plasma concentration as a prognostic index for outcome in patients with septic shock. *Crit. Care Med.* **28**, 3198–3202 (2000).
11. Haynes, J. B., Obitako, B., Thompson, W. J. & Downey, J. Adenosine-induced vasodilation: receptor characterization in pulmonary circulation. *Am. J. Physiol.* **268**, H1862–1868 (1995).
12. Ali, S., Mustafa, S. J. & Metzger, W. J. Adenosine receptor-mediated bronchoconstriction and bronchial hyperresponsiveness in allergic rabbit model. *Am. J. Physiol.* **266**, L271–277 (1994).
13. Ali, S., Mustafa, S. J. & Metzger, W. J. Adenosine-induced bronchoconstriction and contraction of airway smooth muscle from allergic rabbits with late-phase airway obstruction: evidence for an inducible adenosine A1 receptor. *J. Pharmacol. Exp. Ther.* **268**, 1328–1334 (1994).
14. Bours, M. J., Swennen, E. L., Di Virgilio, F., Cronstein, B. N. & Dagnelie, P. C. Adenosine 5’-triphosphate and adenosine as endogenous signaling molecules in immunity and inflammation. *Pharmacol. Ther.* **112**, 358–403 (2006).
15. Hayashi, T. et al. ATP regulation of ciliary beat frequency in rat tracheal and distal airway epithelium. *Exp. Physiol.* **90**, 535–544 (2005).
16. Allen-Gipson, D. S. et al. Adenosine activation of A2B receptor(s) is essential for stimulated epithelial ciliary motility and clearance. *Am. J. Physiol. Lung Cell Mol. Physiol.* **301**, L171–180 (2011).
17. Rice, W. R. & Singleton, F. M. P2Y-purinoceptor regulation of surfactant secretion from rat isolated alveolar type II cells is associated with mobilization of intracellular calcium. *Br. J. Pharmacol.* **91**, 833–838 (1987).
18. Kolosova, I. A. et al. Protective effect of purinergic agonist ATPγPₗ₆5S against acute lung injury. *Am. J. Physiol. Lung Cell Mol. Physiol.* **294**, L319–324 (2008).
19. Gonzalez, J. N. et al. Protective effect of adenosine receptors against lipopolysaccharide-induced acute lung injury. *Am. J. Physiol. Lung Cell Mol. Physiol.* **306**, L497–507 (2014).
20. Cooke, B. et al. Extracellular ATP protects against sepsis through macrophage P2X7 purinergic receptors by enhancing intracellular bacterial killing. *FASEB J.* **29**, 3626–3637 (2015).
21. Cooke, B. et al. A2B adenosine receptors protect against sepsis-induced mortality by dampening excessive inflammation. *J. Immunol.* **185**, 542–550 (2010).
22. Hsu, K., Wang, D., Wu, S. Y., Chen, C. Y. & Chen, H. I. Ischemia-reperfusion lung injury attenuated by ATP-MgCl2 in rats. *J. Surg. Res.* **185**(5), 455–552 (1994).
23. Gazoni, L. M. et al. Activation of A1, A2a, or A3 adenosine receptors attenuates lung ischemia-reperfusion injury. *J. Thorac. Cardiovasc. Surg.* **140**, 440–446 (2010).
24. Geary, C. et al. Increased susceptibility of purinergic receptor-deficient mice to lung infection with *Pseudomonas aeruginosa*. *Am. J. Physiol. Lung Cell Mol. Physiol.* **289**, L890–895 (2005).
25. Xiang, Y. et al. Adenosine 5’-triphosphate (ATP) protects mice against bacterial infection by activation of the NLRP3 inflammasome. *PloS ONE* **8**, e59019 (2013).
26. Bou Ghanem, E. N. et al. Extracellular adenosine protects against streptococcus pneumoniae lung infection by regulating pulmonary neutrophil recruitment. *PloS Pathog.* **11**, e1005126 (2015).
27. Kovacs-Kasa, A. et al. The protective role of MLCP-mediated ERM dephosphorylation in endothotoxin-induced lung injury in vitro and in vivo. *Sci. Rep.* **6**, 39018 (2016).
28. Xie, J. et al. Characterization of myosin phosphatase in endothelium. *J. Cell Biol.* **227**, 1701–1708 (2012).
29. Batori, R. et al. Differential mechanisms of adenosine- and ATPγS-induced microvascular endothelial barrier strengthening. *J. Cell Physiol.* **234**, 5863–5879 (2019).
30. Kolosova, I. A. et al. Signaling pathways involved in adenosine triphosphate-induced endothelial cell barrier enhancement. *Circ. Res.* **97**, 115–124 (2005).
31. Aggarwal, S. et al. Dimethylarginine dimethylaminohydrolase II overexpression attenuates LPS-mediated lung leak in acute lung injury. *Am. J. Respir. Crit. Care Med.* **190**, 614–625 (2014).
32. Matute-Bello, G. et al. An official American Thoracic Society workshop report: features and measurements of experimental acute lung injury in animals. *Am. J. Respir. Crit. Care Med.* **144**, 725–738 (2011).
33. Rafikov, R. et al. Lipopolysaccharide-induced lung injury involves the nitration-mediated activation of RhoA. *J. Biol. Chem.* **284**, 4710–4722 (2014).
34. Umapathy, N. S. et al. Molecular mechanisms involved in adenosine-induced endothelial cell barrier enhancement. *Vasc. Pharmacol.* **52**, 199–206 (2010).
35. Lucas, R., Verin, A. D., Black, S. M. & Catravas, J. D. Regulators of endothelial and epithelial barrier integrity and function in acute lung injury. *Biochem. Pharmacol.* **77**, 1763–1772 (2009).
36. Rudkowski, J. C. et al. Roles of iNOS and nNOS in sepsis-induced pulmonary apoptosis. *Am. J. Physiol. Lung Cell Mol. Physiol.* **286**, L793–800 (2004).
Chuang, C. Y. et al. Lipopolysaccharide induces apoptotic insults to human alveolar epithelial A549 cells through reactive oxygen species-mediated activation of an intrinsic mitochondrion-dependent pathway. *Arch. Toxicol.* **85**, 209–218 (2011).

Ali, A. et al. Effects of ATP-magnesium chloride on the cardiopulmonary manifestations of group B streptococcal sepsis in the piglet. *Pediatr. Res.* **39**, 609–615 (1996).

Moncao-Ribeiro, L. C. et al. Lipopolysaccharide-induced lung injury: role of P2X7 receptor. *Respir. Physiol. Neurobiol.* **179**, 314–325 (2011).

Chen, Y. et al. ATP release guides neutrophil chemotaxis via P2Y2 and A3 receptors. *Science* **314**, 1792–1795 (2006).

Save, S. & Persson, K. Extracellular ATP and P2Y receptor activation induce a proinflammatory host response in the human urinary tract. *Infect. Immun.* **78**, 3609–3615 (2010).

Gavala, M. L. et al. Nucleotide receptor P2RX7 stimulation enhances LPS-induced interferon-beta production in murine macrophages. *J. Leukoc. Biol.* **94**, 759–768 (2013).

Chiao, C. W., Tostes, R. C. & Webb, R. C. P2X7 receptor activation amplifies lipopolysaccharide-induced vascular hyporeactivity via interleukin-1 beta release. *J. Pharmacol. Exp. Ther.* **326**, 864–870 (2008).

Duncan, J. A. et al. Cryopyrin/NALP3 binds ATP/ADP, is an ATPase, and requires ATP binding to mediate inflammatory signaling. *Proc. Natl. Acad. Sci. U S A* **104**, 8041–8046 (2007).

Radian, A. D., Khare, S., Chu, L. H., Dorfleutner, A. & Stehlík, C. ATP binding by NLRP7 is required for inflammasome activation in response to bacterial lipopeptides. *Mol. Immunol.* **67**, 294–302 (2015).

Baron, L. et al. The NLRP3 inflammasome is activated by nanoparticles through ATP ADP and adenosine. *Cell Death Dis.* **6**, e1629 (2015).

Hasko, G., Kuhel, D. G., Salzman, A. L. & Szabo, C. ATP suppression of interleukin-12 and tumour necrosis factor-alpha release from macrophages. *Br. J. Pharmacol.* **129**, 909–914 (2000).

Ngamsri, K. C., Wagner, R., Vollmer, I., Stark, S. & Reutershan, J. Adenosine receptor A1 regulates polymorphonuclear cell trafficking and microvascular permeability in lipopolysaccharide-induced lung injury. *J. Immunol.* **185**, 4374–4384 (2010).

Wagner, R., Ngamsri, K. C., Stark, S., Vollmer, I. & Reutershan, J. Adenosine receptor A3 is a critical mediator in LPS-induced pulmonary inflammation. *Am. J. Physiol. Lung Cell Mol. Physiol.* **299**, L502–510 (2011).

Folkesson, H. G., Kuzenko, S. R., Lipson, D. A., Matthy, M. A. & Simmons, M. A. The adenosine 2A receptor agonist GW328267C improves lung function after acute lung injury in rats. *Am. J. Physiol. Lung Cell Mol. Physiol.* **303**, L259–271 (2012).

Eckle, T., Grenz, A., Laucher, S. & Eltzschig, H. K. A2B adenosine receptor signaling attenuates acute lung injury by enhancing alveolar fluid clearance in mice. *J. Clin. Invest.* **118**, 3301–3315 (2008).

Li, J. et al. Chronic or high dose acute caffeine treatment protects mice against oleic acid-induced acute lung injury via an adenosine A2A receptor-independent mechanism. *Eur. J. Pharmacol.* **654**, 295–303 (2011).

Hasko, G. et al. Adenosine A2A receptor activation reduces lung injury in trauma/hemorrhagic shock. *Crit. Care Med.* **34**, 1119–1125 (2006).

Ross, S. D. et al. Selective adenosine-A2A activation reduces lung reperfusion injury following transplantation. *J. Heart Lung Transplant.* **18**, 994–1002 (1999).

Rivo, J., Zeira, E., Galun, E. & Matot, I. Activation of A3 adenosine receptors attenuates lung injury after in vivo reperfusion. *Anesthesiology* **101**, 1153–1159 (2004).

Sakamaki, F. et al. Attenuation by intravenous 2-chloroadenosine of acute lung injury induced by live escherichia coli or latex particles added to endotoxin in the neutropenic state. *J. Lab. Clin. Med.* **142**, 128–135 (2003).

Barlettta, K. E., Ley, K. & Mehrad, B. Regulation of neutrophil function by adenosine. *Arterioscler. Thromb. Vasc. Biol.* **32**, 856–864 (2012).

Bouma, M. G., van den Wildenberg, F. A. & Buurman, W. A. Adenosine inhibits cytokine release and expression of adhesion molecules by activated human endothelial cells. *Am. J. Physiol.* **270**, C522–529 (1996).

Barlettta, K. E., Cagnina, R. E., Burdick, M. D., Linden, I. & Mehrad, B. Adenosine A(2B) receptor deficiency promotes host defenses against gram-negative bacterial pneumonia. *Am. J. Respir. Crit. Care Med.* **186**, 1044–1050 (2012).

Belkoff, B. G. et al. A2B adenosine receptor blockade enhances macrophage-mediated bacterial phagocytosis and improves polymicrobial sepsis survival in mice. *J. Immunol.* **186**, 2444–2453 (2011).

Hasko, G. et al. Ecto-5’-nucleotidase (CD73) decreases mortality and organ injury in sepsis. *J. Immunol.* **187**, 4256–4267 (2011).

Acknowledgements

This research was supported by grant P01HL0101902 (to ADV and DJF) from the National Institutes of Health and American Heart Association Postdoctoral Fellowship 18POST33990193 (to AKK).

Author contributions

C.M.G.: Study design, data acquisition, analysis, interpretation, and writing of the manuscript; A.K.K.: Data acquisition, analysis, interpretation and manuscript submission; M.L.M.: Data acquisition and analysis; M.C.S.: Data acquisition and analysis; D.J.E.: Data interpretation and writing of the manuscript; A.D.V.: Study design, analysis, interpretation, and writing of the manuscript.

Competing interests

The authors declare no competing interests.

Additional information

Supplementary information is available for this paper at https://doi.org/10.1038/s41598-020-75224-0.

Correspondence and requests for materials should be addressed to A.D.V.

Reprints and permissions information is available at www.nature.com/reprints.

Publisher’s note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
